Medtronic's Stealth AXiS™ Gains FDA Nod: Advanced Precision for Brain & ENT Procedures

GALWAY, Ireland, March 27, 2026 – Medtronic (NYSE: MDT), a prominent global innovator in healthcare technology, revealed today that its Stealth AXiS™ surgical system has secured U.S. Food and Drug Administration (FDA) clearance. This approval permits the system's application in cranial and ear, nose, and throat (ENT) procedures.

Having received FDA clearance for spinal procedures in February, the Stealth AXiS™ surgical system integrates surgical planning, navigation, and robotics into a single intelligent platform. This comprehensive system is engineered to offer surgeons heightened precision and critical real-time insights when performing complex operations.

According to Ranked Stocks data, Medtronic (MDT) holds an RS Score of 75.42, placing it in the 71.74th percentile within both its country and sector. The company demonstrates strong performance in Valuation (93.48) and Profitability (85.93). Conversely, areas such as Growth (65.69), Momentum (48.61), and EPS Revisions (70.00) appear to be weaker. Want to discover which stocks rank the highest? Start your free 7-day trial at rankedstocks.com.